Detalles de la búsqueda
1.
Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.
Ann Hematol
; 103(1): 5-15, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37804344
2.
[Japanese patient preferences between ravulizumab and eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria].
Rinsho Ketsueki
; 64(1): 9-17, 2023.
Artículo
en Japonés
| MEDLINE | ID: mdl-36775313
3.
Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data.
Clin Nephrol
; 97(5): 261-272, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-34931610
4.
Atypical Hemolytic Uremic Syndrome Treated With Ravulizumab or Eculizumab: A Claims-Based Evaluation of Health Care Resource Utilization and Clinical Outcomes in the United States.
Kidney Med
; 5(8): 100683, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37415624
5.
The burden of mitochondrial disease with associated seizures: systematic literature reviews of health-related quality of life, utilities, costs and healthcare resource use data.
Orphanet J Rare Dis
; 18(1): 320, 2023 10 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37821990
6.
Clinically important change for the FACIT-Fatigue scale in paroxysmal nocturnal hemoglobinuria: a derivation from international PNH registry patient data.
J Patient Rep Outcomes
; 7(1): 63, 2023 07 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37405515
7.
Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome.
J Comp Eff Res
; 12(9): e230036, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37515502
8.
Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome.
J Med Econ
; 25(1): 249-259, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35020547
9.
Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Large, Multicenter, US Real-World Study.
J Blood Med
; 13: 425-437, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35983240
10.
Concept confirmation of the Treatment Administration Satisfaction Questionnaire (TASQ) in rare paroxysmal nocturnal hemoglobinuria.
J Patient Rep Outcomes
; 5(1): 45, 2021 Jun 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-34152498
11.
Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria.
Pharmacoeconomics
; 38(9): 981-994, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32519233
12.
Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab.
Hematology
; 25(1): 327-334, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32856539
13.
A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome.
J Med Econ
; 23(12): 1503-1515, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-33001704
14.
Functional Assessment of Fatigue and Other Patient-Reported Outcomes in Patients Enrolled in the Global aHUS Registry.
Kidney Int Rep
; 5(8): 1161-1171, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32775815
15.
Assessing Preferences for Rare Disease Treatment: Qualitative Development of the Paroxysmal Nocturnal Hemoglobinuria Patient Preference Questionnaire (PNH-PPQ©).
Patient Prefer Adherence
; 14: 705-715, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32308375
16.
Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.
PLoS One
; 15(9): e0237497, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32886668
17.
Reliability and Validity of the 6-Minute Walk Test in Hypophosphatasia.
JBMR Plus
; 3(6): e10131, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-31346563
18.
Frequency and age at occurrence of clinical manifestations of disease in patients with hypophosphatasia: a systematic literature review.
Orphanet J Rare Dis
; 14(1): 85, 2019 04 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-31023354
19.
Technologies for continuous glucose monitoring: current problems and future promises.
J Diabetes Sci Technol
; 4(6): 1540-62, 2010 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21129353
20.
Emerging synergy between nanotechnology and implantable biosensors: a review.
Biosens Bioelectron
; 25(7): 1553-65, 2010 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20042326
Resultados
1 -
20
de 20
1
Próxima >
>>